Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review
Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G
BMJ (Clinical research ed.) · 375 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2006-03-24 · BMJ · vol. 332 · número 7544 · págs. 752–760
- Citado
- 679 citas · más que el 100% de estudios similares · 8.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 26 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Fatty Acid Research and Health · Nutritional Studies and Diet · Edible Oils Quality and Analysis
- Palabras clave
- omega-3 fatty acids, all-cause mortality, cardiovascular events, cancer risk, dietary supplementation, cardiovascular disease prevention
- MeSH
- humans, neoplasms, cardiovascular diseases, fatty acids, omega-3, fish oils, prognosis, risk factors, cohort studies, dietary supplements, randomized controlled trials as topic
13 autores
- Lee Hooper🇬🇧 · autor de correspondenciaUniversity of East Anglia
- Rachel L Thompson🇬🇧University of Southampton
- R. Steven Harrison🇬🇧Bolton NHS Foundation Trust
- Carolyn Summerbell🇬🇧Teesside University
- Andy Ness🇬🇧University of Bristol
- Helen J. Moore🇬🇧Teesside University
- Helen V Worthington🇬🇧University of Manchester
- Paul N. Durrington🇬🇧University of Manchester
- Julian P. T. Higgins🇬🇧MRC Biostatistics Unit
- Nigel E. Capps🇬🇧Shrewsbury and Telford Hospital NHS Trust
- Rudolph Arend Riemersma🇬🇧University of Edinburgh
- Shah B J Ebrahim🇬🇧London School of Hygiene & Tropical Medicine
- George Davey Smith🇬🇧University of Bristol
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To review systematically the evidence for an effect of long chain and shorter chain omega 3 fatty acids on total mortality, cardiovascular events, and cancer.
Data sources
Electronic databases searched to February 2002; authors contacted and bibliographies of randomised controlled trials (RCTs) checked to locate studies.
Review methods
Review of RCTs of omega 3 intake for (3) 6 months in adults (with or without risk factors for cardiovascular disease) with data on a relevant outcome. Cohort studies that estimated omega 3 intake and related this to clinical outcome during at least 6 months were also included. Application of inclusion criteria, data extraction, and quality assessments were performed independently in duplicate.
Results
Of 15,159 titles and abstracts assessed, 48 RCTs (36,913 participants) and 41 cohort studies were analysed. The trial results were inconsistent. The pooled estimate showed no strong evidence of reduced risk of total mortality (relative risk 0.87, 95% confidence interval 0.73 to 1.03) or combined cardiovascular events (0.95, 0.82 to 1.12) in participants taking additional omega 3 fats. The few studies at low risk of bias were more consistent, but they showed no effect of omega 3 on total mortality (0.98, 0.70 to 1.36) or cardiovascular events (1.09, 0.87 to 1.37). When data from the subgroup of studies of long chain omega 3 fats were analysed separately, total mortality (0.86, 0.70 to 1.04; 138 events) and cardiovascular events (0.93, 0.79 to 1.11) were not clearly reduced. Neither RCTs nor cohort studies suggested increased risk of cancer with a higher intake of omega 3 (trials: 1.07, 0.88 to 1.30; cohort studies: 1.02, 0.87 to 1.19), but clinically important harm could not be excluded.
Conclusion
Long chain and shorter chain omega 3 fats do not have a clear effect on total mortality, combined cardiovascular events, or cancer.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.